Anti-CD9, clone Z9.1

Application

Immunohistochemistry Analysis: A 1:1,000 dilution from a representative lot detected CD9 in human tonsil, human breast cancer, and human skin tissues.

Flow Cytometry Analysis: A 1:1,000 dilution from a representative lot detected CD9 in human PBMCs.
human tonsil, human breast cancer, human liver cancer, human skin

This mouse monoclonal Anti-CD9 antibody, clone Z9.1, Cat. No. MABT914, is validated for use in ELISA, Flow Cytometry, Immunohistochemistry (Paraffin), and Western Blotting for the detection of CD9.

General description

CD9 antigen (UniProt: P21926; also known as 5H9 antigen; Cell growth-inhibiting gene 2 protein; Leukocyte antigen MIC3; Motility-related protein; MRP-1; Tetraspanin-29; Tspan-29; p24) is encoded by the CD9 (also known as MIC3, TSPAN29; IG2) gene (Gene ID: 928) in human. CD9 is a multi-pass membrane glycoprotein of the tetraspanin (TM4SF) family. It is expressed in a variety of hematopoietic and epithelial cells. It displays strong expression in platelets where it mediates platelet activation and aggregation upon binding to monoclonal antibodies. CD9 induces cell-cell adhesion, platelet aggregation, and B cell development and is shown to associate with CD63, CD81, CD82, and CD36 and to bind to beta-1 integrins. CD9 activation of platelets is reported to be mediated by the Fc y RII (CD32) molecule. Downregulation of CD9 correlates with tumor progression in some forms of cancer. It can hamper metastasis formation by inhibiting integrin-mediated motility. Lower expression of CD9 are associated with weaker matrix adhesion and diffuse tumor cell growth in vitro.

Immunogen

Intact LoVo colorectal carcinoma cells.

Other Notes

Concentration: Please refer to lot specific datasheet.

Physical form

Format: Purified

Quality

Evaluated by Immunohistochemistry in human human liver cancer tissue.

Immunohistochemistry Analysis: A 1:1000 dilution of this antibody detected CD9 in human liver cancer tissue.

Specificity

Clone Z9.1 detects CD9 in its native, non-reduced form, in CD-9 positive cells amongst human PBMCs.

Target description

25.42 kDa calculated